Pharmacy
New Page Title

Home

Psychotropic drugs
New Page Title
My Favorite medications
What can i take for..
Nasal Sprays
New Page Title
Xylometazoline
Links to Drugstores online
Top 200
New Page Title
Drug schedule 1
Drug schedule 2
Drug scedule 3
Newsletter
Patient Resources
New Page Title
New Page Title
Motion sickness
Serotonin
Pseudoephedrine

Enter subhead content here


SCHEDULE 1

1 The drugs included in this Schedule shall be

(a) dispensed for sale by a pharmacist only pursuant to a
prescription, and

(b) in a licensed pharmacy, stored for sale to the public only in
the prescription department.

2(1) The drugs in this Schedule include:

(a) drugs set out in the Schedule to the Narcotic Control Act
(Canada);

(b) drugs set out in Schedule G to the Food and Drugs Act (Canada);

(c) drugs set out in Schedule F to the regulations under the Food
and Drugs Act (Canada);

(c.1) drugs designated as Schedule 1 drugs by regulation under
section 92;

(d) the following drugs:

aconite (except in trace amounts in homeopathic preparations);
alverine and its salts for parenteral use;
aminopromazine (proquamezine) and its salts;
arsenic and its salts and compounds for human use (except in trace
amounts in homeopathic preparations);
aspidium for oral use (except in trace amounts in homeopathic
preparations);
azathioprine and its salts;
bacitracin and its salts and derivatives for parenteral use;
chenopodium ambrosioides;
cycrimine;
ephedrine and its salts (products for internal use containing ephedrine and its salts as the single active ingredient);
erythrityl tetranitrate;
ethopropazine hydrochloride (profenamine and its salts);
ethylpapaverine and its salts;
flumazenil;
homatropine and its salts (for ophthalmic or parenteral use
or in preparations for oral use containing more than 2 mg per
dosage unit);
isopropamide and its salts;
isosorbide dinitrate;
levallorphane and its salts;
metaraminol bitartrate;
methacholine and its salts;
nicotinyl tartrate;
nikethamide;
nitroglycerin (except for sublingual immediate release
dosage forms);
orphenadrine hydrochloride;
pancreatic enzymes (cystic fibrosis treatment);
pancreatin;
pancrelipase;
papaveretrine and its salts;
papaverine and its salts;
paramomycin;
pentaerythritol tetranitrate;
quinacrine;
quinidine and its salts;
streptokinase/streptodornase
succinylcholine and its salts;
tubocurarine and its salts;
vaccines;
vitamin D in preparations containing more than 1000 IU
per recommended daily dose;
vitamin K.

(e) pentazocine.

(2) Drugs referred to in subsection (1)(a) shall be dispensed in
accordance with the Narcotic Control Act (Canada) and the regulations under
that Act.

(3) Drugs referred to in subsection (1)(b) and (c) shall be dispensed in
accordance with the Food and Drugs Act (Canada) and the regulations under
that Act.

(4) Drugs referred to in subsection (1)(d) shall be dispensed or sold
under the same conditions that apply to drugs listed in Part II of Schedule
F to the regulations under the Food and Drugs Act (Canada).

(5) The drug referred to in subsection (1)(e) shall be dispensed

(a) only on a written prescription, and

(b) in a licensed pharmacy, subject to the conditions prescribed in
the regulations.
1988 cP-7.1 Sched.1;AR 136/98;AR 137/98;1999 c26 s17;
AR 261/99


SCHEDULE 2

1 The drugs included in this Schedule shall be

(a) sold only in a pharmacy,

(b) sold only by or under the direct supervision of a pharmacist,
and

(c) in a licensed pharmacy, stored for sale to the public only in
the prescription department.

2 No member or proprietor shall, in advertising a drug included in this
Schedule, make a representation other than with respect to the name, price
and quantity of the drug.

2.1 The drugs in this Schedule include drugs designated as Schedule 2
drugs by regulation under section 92.

3 The drugs in this Schedule include:

acetarsol;

acetylcysteine;

acetylsalicylic acid and its salts (in oral preparations containing
80 mg or less per dosage unit);

allergy serums;

allethrins;

anisotropine and its salts;

anthralin (dithranol);

antihemophilic factor, human;

antipyrine (except otic preparations);

apomorphine and its salts;

arginine and its salts;

artemisia and its preparations, extracts and compounds (except in
trace amounts in homeopathic preparations);

azelaic acid;

bacitracin and its salts and derivatives (for ophthalmic use);

belladonna alkaloids and their salts and derivatives (except in
preparations for topical use or in trace amounts in homeopathic
preparations);

bengal rose;

bentiromide;

benzalkonium and its salts (liquid preparations in concentrations of
more than 2%);

benzethonium chloride (liquid preparations in concentrations of more
than 1%);

benzocaine and its salts (for parenteral or ophthalmic use);

boric acid and its salts (in preparations for systemic use or in
ophthalmic preparations in concentrations over 2%);

buclizine;

bufexamac;

calcium disodium edetate;

camphor (in oleaginous vehicles and in liquid forms in concentrations
greater than 11%);

cantharides and its derivatives and preparations;

cholecystokinin;

chymotrypsin (ophthalmic);

clidinium and its salts;

coal tar (in concentrations of more than 10%);

collagenase (as a debriding agent);

cyclandelate;

cyclazocine and its salts;

cyclopentamine and its salts;

cyclopentolate and its salts (except for ophthalmic and parenteral
use);

cyproheptadine and its salts;

desoxyribonuclease (pancreatin dornase);

dextrose (sclerosing agents);

dicyclomine and its salts (except for topical use and lozenges);

dihydroquinidine and its salts (except phenylbarbiturate);

diiodohydroxyquine (topicals);

dimenhydrinate and its salts (oral or rectal);

diperodon and its salts (except for topical use);

drugs for human use not included in Schedule 1 that are intended for
administration by hypodermic injection;

dyclonine (except for topical use on mucous membranes);

electrolyte solutions (except in oral rehydration preparations);

epinephrine and its salts;

ethanolamine oleate;

ethoheptazine and its salts;

ethyl chloride (except in trace amounts);

fibrin;

fibrinolysin;

fluorides for oral or topical use (except in dentifrices and
mouthwashes and in preparations containing less than 0.45 mg of fluorine
(equivalent to 0.1 mg of sodium fluoride) per daily recommended dose);

glucagon;

glutamic acid and its salts (gastric acidifiers);

glycopyrrolate and its salts;

gramicidin and its salts and derivatives (for ophthalmic use);

heparin and its salts (except for topical use);

histamine and its salts (except for topical use);

homatropine and its salts (for oral use in concentrations of 2 mg or
less per dosage unit);

hyaluronic acid and its salts (preparations in concentrations of 5%
or more);

hyaluronidase;

hydroquinone (topical preparations in concentrations of 2% or more);

hydroxyephedrine and its salts;

hyoscine and its salts and derivatives (scopolamine);

hyoscyamine and its salts and derivatives (except for topical use);

insulin;

iodinated casein;

iodinated glycerol;

iodine and its salts and derivatives (except topical preparations or
in oral doses of 1 mg or less per day);

iodochlorhydroxyquine (for topical use);

ipecac and its extracts and derivatives when used as an emetic;

iron and its salts and derivatives (preparations with more than 30
mg elemental iron per solid dosage unit or 5 ml oral liquid);

levargorphane and its salts;

levonordefrin;

lidocaine and prilocaine (eutectic mixture);

local anaesthetics for ophthalmic use;

loperamide and its salts (oral liquid dosage forms for children);

mannitol and its salts;

metathoheptazine and its salts;

methantheline and its salts;

methdilazine and its salts;

methenamine and its salts (except for topical use);

metheptazine and its salts;

methyl salicylate (oil of wintergreen) liquid dosage forms in
concentrations greater than 30%;

monobenzone;

monoethanolamine oleate;

mupirocin;

naphazoline and its salts (in nasal preparations for paediatric use);

niacin (as a single ingredient with more than 50 mg per dosage unit
in extended release formulations);

nitroglycerin (sublingual immediate release dosage forms);

norepinephrine and its salts (levarterenol, noradrenaline);

oxymetazoline and its salts in nasal preparations for paediatric use;

oxyquinoline;

papain (as a debriding agent);

paroxypropione;

pentagastrin and its salts;

phenol (preparations in concentrations of more than 20%);

phenoxybenzamine and its salts;

phenylephrine and its salts and preparations (in nasal preparations
in concentrations of 2.5% or less, for paediatric use);

phenylpropanolamine and its salts and preparations (in preparations
containing more than 50 mg per single dose of an immediate release
preparation, or more than 75 mg per single dose of a controlled or
sustained release preparation, or preparations for which the recommended
total daily dose is greater than 150 mg);

physostigmine salicylate (oral or topical);

pinaverium and its salts;

piperazine and its salts;

polyacrylamide;

polymixin B and its salts and derivatives (for ophthalmic use);

potassium salts (preparations containing more than 5 mmol per single
dose);

promethazine and its salts (except for topical use);

propantheline and its salts;

propylhexedrine;

protamine and its salts;

pyrantel and its salts;

pyrvinium and its salts;

quinine salts;

racemethionine;

rue and its preparations and extracts;

salicylic acid and its salts in topical preparations in
concentrations of more than 40%;

silver nitrate;

sincalide;

sodium chloride (single ingredient solutions and ophthalmic
preparations in concentrations of more than 0.9%);

sodium iodide (for sclerosing);

sodium tetradecylsulfate;

stramonium and its preparations, extracts and compounds;

streptokinase (as a debriding agent);

sutilains;

tetrahydrazoline (in nasal preparations for paediatric use);

thrombin;

thyroglobulin;

thyrotropin;

urea (topical preparations in concentrations of more than 25%);

xylometazoline and its salts in preparations for paediatric use;

xylose.


4(1) A product that is removed from Schedule F to the regulations under
the Food and Drugs Act (Canada) and approved for non-prescription sale in
Canada shall be included in this Schedule.

(2) The inclusion of a drug in this Schedule pursuant to subsection (1)
shall be reassessed every 2 years.
1988 cP-7.1 Sched. 2;AR 136/98;1999 c26 s17;AR 261/99


SCHEDULE 3

1 The drugs included in this Schedule shall be

(a) sold only in a pharmacy, and

(b) in a licensed pharmacy, displayed in the professional products
department or stored for sale to the public in the prescription department.

2 No member or proprietor shall, in advertising a drug included in this
Schedule, make a representation other than with respect to the name, price
and quantity of the drug.

2.1 The drugs in this Schedule include drugs designated as Schedule 3
drugs by regulation under section 92.

3 The drugs in this Schedule include:

(a) belladonna alkaloids and their salts and derivatives for
topical use;

(a.1) benzocaine and its salts (for topical use on mucous membranes
for teething);

(b) benzoyl peroxide (as a single active ingredient, in
concentrations of 5% or less)

(c) benzyl benzoate;

(c.1) bisacodyl and its salts;

(d) cetirizine in concentrations equal to or less than 8.5 mg
cetirizine per dosage form;

(e) cimetidine and its salts (in concentrations of 100 mg or less
per dosage unit);

(f) clotrimazole and its salts (in preparations for intra-vaginal
use);

(g) crotamiton;

(h) drugs for veterinary use by hypodermic injection into an
animal;

(i) dyclonine and its salts (for topical use on mucous membranes,
except lozenges);

(j) esdepallethrin/piperonyl butoxide;

(k) famotidine and its salts (in preparations for oral use
containing 10 mg or less of famotidine per dosage unit);

(l) fexofenadine hydrochloride;

(m) heparin and its salts (for topical use);

(n) hydrocortisone and hydrocortisone acetate (as a single active
ingredient, in topical preparations in concentrations of 0.5% or less);

(o) ibuprofen and its salts in concentrations of 200 mg or less of
ibuprofen per dosage form;

(p) repealed AR 261/99 s4;

(q) lindane;

(q.1) local anaesthetics (for topical use on mucous membranes, except
lozenges);

(r) loperamide and its salts (in solid dosage forms);

(r.1) methocarbamol (except for parenteral use);

(s) miconazole and its salts (in preparations for intra-vaginal
use);

(t) nicotine and its salts when sold as a chewing gum containing 4
mg or less of nicotine per dosage unit;

(t.1) nicotine transdermal patches with a delivery rate of less than
22 mg nicotine daily;

(u) nystatin and its salts and derivatives (for topical or vaginal
use);

(u.1) orphenadrine citrate;

(v) permethrin and its derivatives;

(w) piperonyl and its salts;

(x) pyrethrins;

(y) pyrethrins/piperonyl butoxide;

(z) repealed AR 261/99 s4;

(aa) saccharin;

(bb) sodium cromoglycate in solutions for ophthalmic or nasal use in
concentrations of 2% or less;

(cc) tioconazole and its salts (in preparations for intra-vaginal
use).

Enter supporting content here